MEDIPOST Co., Ltd.

A078160

KR7078160009

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
6,980 ^KRW	+1.60%		-3.59%	-14.46%

04-24	Medip MEDIPOST CDMO Co., Ltd. announced that it has received KRW 30 billion in funding from MEDIPOST Co., Ltd.	CI
04-23	Medip MEDIPOST CDMO Co., Ltd. announced that it expects to receive KRW 30 billion in funding from MEDIPOST Co., Ltd.	CI

MEDIPOST America, Inc. announced that it has received KRW 45.6715 billion in funding from MEDIPOST Co., Ltd.

May 21, 2023

On May 22, 2023, MEDIPOST America, Inc. closed the transaction.

Latest news about MEDIPOST Co., Ltd.

Medip MEDIPOST CDMO Co., Ltd. announced that it has received KRW 30 billion in funding from MEDIPOST Co., Ltd.	04-23	CI
Medip MEDIPOST CDMO Co., Ltd. announced that it expects to receive KRW 30 billion in funding from MEDIPOST Co., Ltd.	04-22	CI
MEDIPOST America, Inc. announced that it expects to receive KRW 41.418 billion in funding from MEDIPOST Co., Ltd.	04-22	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Medip MEDIPOST CDMO Co., Ltd. announced that it has received KRW 15 billion in funding from MEDIPOST Co., Ltd.	23-07-03	CI
Medip MEDIPOST CDMO Co., Ltd. announced that it expects to receive KRW 15 billion in funding from MEDIPOST Co., Ltd.	23-06-26	CI
MEDIPOST America, Inc. announced that it has received KRW 45.6715 billion in funding from MEDIPOST Co., Ltd.	23-05-21	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
MEDIPOST America, Inc. announced that it expects to receive KRW 45.6715 billion in funding from MEDIPOST Co., Ltd.	23-03-14	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Medipost to Raise Nearly $58 Million via Stock Offering	22-03-18	MT
MEDIPOST Co., Ltd. announced that it expects to receive KRW 139.99997651 billion in funding	22-03-15	CI
MEDIPOST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-14	CI
Celino Co., Ltd. cancelled the contract to acquire CM business division of MEDIPOST Co., Ltd	20-01-31	CI
MEDIPOST Co., Ltd. announced that it has received KRW 40 billion in funding	19-03-25	CI
MEDIPOST Co., Ltd. announced that it expects to receive KRW 40 billion in funding	19-03-07	CI
Celino Co., Ltd. signed a contract to acquire CM business division of MEDIPOST Co., Ltd. for approximately KRW 940 million.	19-01-31	CI
Medipost to Form Joint Venture with Jingyuan Bio-Tech, Ltd	14-12-09	CI
Medipost Co Ltd announced that it has received KRW 10.10 billion in funding from Seoul Investments & Susung & E-um PEF.	14-10-13	CI
Medipost Co Ltd announced that it has received KRW 20 billion in funding from KDB Capital Corp., IBK Capital Corporation, Susung Asset Management Co., Ltd., Kiwoom Investment Co., Ltd..	14-07-03	CI
Medipost Co Ltd announced that it expects to receive KRW 20 billion in funding from KDB Capital Corp., IBK Capital Corporation, Susung Asset Management Co., Ltd., Kiwoom Investment Co., Ltd..	14-07-02	CI

MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDIPOST CO., LTD.	-14.46%	176M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B

Other Biotechnology & Medical Research

MEDIPOST Co., Ltd.

Equities

A078160

KR7078160009

Biotechnology & Medical Research

MEDIPOST America, Inc. announced that it has received KRW 45.6715 billion in funding from MEDIPOST Co., Ltd.

Latest news about MEDIPOST Co., Ltd.

Chart MEDIPOST Co., Ltd.

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research